Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H8N2O2S.ClH |
Molecular Weight | 208.666 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=CC=C(C=C1)S(N)(=O)=O
InChI
InChIKey=XZMIAZCXISFPEJ-UHFFFAOYSA-N
InChI=1S/C6H8N2O2S.ClH/c7-5-1-3-6(4-2-5)11(8,9)10;/h1-4H,7H2,(H2,8,9,10);1H
Molecular Formula | C6H8N2O2S |
Molecular Weight | 172.205 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.08 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
81.3 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.71 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/27010464 |
10 mg/kg bw single, oral dose: 10 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
SULFANILAMIDE plasma | Capra hircus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: bacterial infection (Candida albicans) Age Group: adult Sex: F Sources: |
Other AEs: Local reaction... Other AEs: Local reaction (0.2%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Local reaction | 0.2% | 15 % 1 times / day steady, topical Recommended Dose: 15 %, 1 times / day Route: topical Route: steady Dose: 15 %, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: bacterial infection (Candida albicans) Age Group: adult Sex: F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Clinico-immunologic effect of immunomodulin and bactim in duodenal ulcer under environmental pollution conditions]. | 2002 |
|
Pneumocystis pneumonia. | 2002 Dec |
|
Iron (III) aquacomplexes as effective photocatalysts for the degradation of pesticides in homogeneous aqueous solutions. | 2002 Oct 21 |
|
Design and synthesis of fluorescent beta-cyclodextrins for the enantioselective sensing of alpha-amino acids. | 2003 |
|
Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. | 2003 |
|
[Treatment of patients with acute pneumonia]. | 2003 Apr-Jun |
|
Measurement of physiological S-nitrosothiols: a problem child and a challenge. | 2003 Aug |
|
Sulphonamide resistance gene sul3 found in Escherichia coli isolates from human sources. | 2003 Dec |
|
Risk factors for antibiotic resistance in Campylobacter spp. isolated from raw poultry meat in Switzerland. | 2003 Dec 9 |
|
[Integrons and antimicrobial resistance gene cassettes in Shigella flexneri strains ]. | 2003 Jul |
|
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. | 2003 Jul 7 |
|
Preserving the chromatographic integrity of high-speed supercritical fluid chromatography separations using time-of-flight mass spectrometry. | 2003 Jul-Aug |
|
Polyelectrolyte Complexes: Interactions between Lignosulfonate and Chitosan. | 2003 Mar-Apr |
|
[Adverse cutaneous reaction to celecoxib: 6 cases]. | 2003 May |
|
Early manifestation of nephropathy in rats with arterial calcinosis. | 2003 May |
|
[Treatment of sulfanilamide production wastewater by resin adsorption technique]. | 2003 Nov |
|
Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine. | 2003 Nov |
|
Facilitation of addition-elimination reactions in pyrimidines and purines using trifluoroacetic acid in trifluoroethanol. | 2003 Nov 21 |
|
Investigation of structural and dynamic features of the radicals produced in gamma irradiated sulfanilamide: an ESR study. | 2003 Nov 28 |
|
Validated HPLC method for the determination of ranitidine in plasma. | 2003 Oct |
|
Synthesis and applications of poly(acryl p-aminobenzenesulfonamideamidine- p-aminobenzenesulfonylamide) chelating fiber for pre-concentrating and separating trace Bi(III), Hg(III), Au(III) and Pd(IV) from solution samples. | 2003 Oct |
|
Carbonic anhydrase inhibitors: inhibition of human and murine mitochondrial isozymes V with anions. | 2003 Sep 1 |
|
Generation of group-specific antibodies against sulfonamides. | 2003 Sep 24 |
|
High-performance liquid chromatography/inductively coupled plasma mass spectrometry and tandem mass spectrometry for the detection of carbon-containing compounds. | 2004 |
|
Simultaneous determination of cefatrizine and clavulanic acid in dog plasma by HPLC. | 2004 Apr 1 |
|
4-sulphamoylphenyl semicarbazones with anticonvulsant activity. | 2004 Aug |
|
Quantitative analysis of twelve sulfonamides in honey after acidic hydrolysis by high-performance liquid chromatography with post-column derivatization and fluorescence detection. | 2004 Aug 20 |
|
A new method for purification of carbonic anhydrase isozymes by affinity chromatography. | 2004 Feb |
|
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. | 2004 Feb 23 |
|
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. | 2004 Feb 26 |
|
Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. | 2004 Feb 9 |
|
Engineering of a broad specificity antibody for simultaneous detection of 13 sulfonamides at the maximum residue level. | 2004 Jan 14 |
|
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. | 2004 Jan 5 |
|
Effects of pig slurry on the sorption of sulfonamide antibiotics in soil. | 2004 Jul |
|
Glucose 6 phosphate dehydrogenase deficiency in adults. | 2004 Jul |
|
Sorption of sulfonamide pharmaceutical antibiotics on whole soils and particle-size fractions. | 2004 Jul-Aug |
|
Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy. | 2004 Jun |
|
Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. | 2004 Jun |
|
[Preparation of monoclonal antibody against sulfadiazine and development of an ELISA kit]. | 2004 Mar |
|
Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. | 2004 Mar |
|
Effects of polymorphic differences for sulfanilamide, as seen through 13C and 15N solid-state NMR, together with shielding calculations. | 2004 Mar |
|
Synthesis and cytotoxic activity of lipophilic sulphonamide derivatives of the benzo[b]thiophene 1,1-dioxide. | 2004 Mar 1 |
|
An experimental animal model of aseptic loosening of hip prostheses in sheep to study early biochemical changes at the interface membrane. | 2004 Mar 3 |
|
Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. | 2004 May 4 |
|
Lessons unlearned. | 2004 May-Jun |
|
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. | 2004 Nov 1 |
|
Drinking-water nitrate, methemoglobinemia, and global burden of disease: a discussion. | 2004 Oct |
|
Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. | 2004 Oct 15 |
|
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats. | 2004 Oct 4 |
|
Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. | 2004 Sep |
Sample Use Guides
One applicatorful (about 6g) intravaginally once or twice daily. Improvements in symptoms should
occur within a few days, but treatment should be continued for a period of 30 days.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24472654
Antimicrobial activity of sulfanilamide was tested with different bacterial and yeast strains. MIC values were 8 ug/ml for Listeria innocua, Escherishia coli and Pseudomonas aeruginosa; 16 ug/ml for Staphylococcus aureu and Candida albicans; 100 ug/ml for Botrytis cinerea and Fusarium oxysporum culmorum.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:16 GMT 2023
by
admin
on
Fri Dec 15 15:26:16 GMT 2023
|
Record UNII |
R2MR7LN8WP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID50209889
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
R2MR7LN8WP
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
80197
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY | |||
|
6101-31-1
Created by
admin on Fri Dec 15 15:26:16 GMT 2023 , Edited by admin on Fri Dec 15 15:26:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |